Tyra Biosciences reported a third quarter 2026 net loss of US$51.1 million and a basic loss per share of US$0.74 as spending on three clinical programs for dabogratinib continued. A recent financing round raised about US$400 million and extended funding visibility through 2030. The same update highlighted early Phase 2 SURF302 data for dabogratinib in FGFR3 altered bladder cancer, where a 79% overall response rate and an oral, potentially long term dosing profile could reshape how...
Tyra Biosciences has delivered a 54.9% gain over the past 3 years, which means anyone looking at the stock today now has to ask whether that share price is still grounded in the company’s book value. For a business at Tyra Biosciences' stage, where hard assets and the balance sheet carry real weight, that question matters more than ever. The 54.9% return over 3 years puts real pressure on the idea that Tyra Biosciences' current valuation is still anchored to what its balance sheet actually...
Tyra Biosciences has delivered a 31.8% gain over the past 3 years, yet the recent pullback in the share price raises a practical question for investors who watch fundamentals closely. Is the current market price meaningfully supported by the company’s book value, or has sentiment moved ahead of what the balance sheet can justify? The stock has returned 31.8% over 3 years, which puts real weight on whether the balance sheet can underpin that kind of share price progress. For a clinical stage...
Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
About This EventTyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]
Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...
Detailed price information for Tyra Biosciences Inc (TYRA-Q) from The Globe and Mail including charting and trades.
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.
Tyra Biosciences (NASDAQ:TYRA) shares dropped 30% on Wednesday after the biotechnology company released initial results from its Phase 2 SURF302 trial of dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. At the 60 mg once-daily dose, dabogratinib produced a 79% overall response rate and a 64% complete response rate as the best overall response among patients with single and multiple marker lesions combined.
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibit
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:
Tyra Biosciences (TYRA) downgraded to Hold ahead of phase 2 SURF302 data; review FGFR3-targeting SNAP platform, cash runway, and key catalysts—read now.
Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.
This is the newest page. Registered accounts read further back.